CompletedNCT03386851
Official study titlePost-Marketing Surveillance of Safety and Effectiveness of Abilify Maintena® Injections in Korean Patients With Schizophrenia or Bipolar 1 Disorder Under the "New Drug Re-Examination"
This study has finished and is no longer accepting participants.
In GwangjuBipolarity, SchizophreniaObservational studyAges 19+
- Countries
- South Korea
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
CompletedNCT00208169
About this title
Abilify Therapy for Reducing Comorbid Substance Abuse
Read the official source — NCT00208169Official study titleAripiprazole (Abilify) Therapy for Reducing Comorbid Substance Abuse
This study has finished and is no longer accepting participants.
In OmahaSchizophrenia, Depression, ...Medication studyAges 19–65
- Countries
- United States
- Sponsor
- Creighton University
CompletedNCT00484471
About this title
ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness
Read the official source — NCT00484471Official study titleA Double Blind, Randomized, Placebo Controlled Trial of Aripiprazole Plus Valproate in the Short-Term and Long-Term Treatment of Bipolar Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including TuenmenBipolarityMedication studyAges 18–65
- Countries
- China, Philippines, Taiwan, + 1 other
- Sponsor
- Korea Otsuka International Asia Arab
CompletedNCT02870218
This study has finished and is no longer accepting participants.
Multiple locations, including CharlotteAddictionMedication studyAges 21–65
- Countries
- United States
- Sponsor
- Rose Research Center, LLC
CompletedNCT00158236
About this title
Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid Users
Read the official source — NCT00158236Official study titleEffects of Buprenorphine/Naloxone in Non-Dependent Opioid Abusers
This study has finished and is no longer accepting participants.
In BaltimoreAddictionMedication studyAges 18–55
- Countries
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
CompletedNCT01323569
Official study titleA Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Abuse Potential of Sativex in Subjects With a History of Recreational Marijuana Use
This study has finished and is no longer accepting participants.
In TorontoAddictionMedication studyAges 19–45
- Countries
- Canada
- Sponsor
- Jazz Pharmaceuticals
CompletedNCT00330174
About this title
Acamprosate in Alcoholics With Comorbid Anxiety or Depression
Read the official source — NCT00330174Official study titleThe Use of Acamprosate in Individuals With Alcohol Dependence and Comorbid Anxiety or Depression
This study has finished and is no longer accepting participants.
Multiple locations, including BelmontDepression, AnxietyMedication studyAges 18–60
- Countries
- United States
- Sponsor
- Medical University of South Carolina
CompletedNCT00511940
About this title
Acamprosate in the Treatment of Binge-Eating Disorder
Read the official source — NCT00511940Official study titleAcamprosate in the Treatment of Binge-Eating Disorder
This study has finished and is no longer accepting participants.
In MasonEating disordersMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Lindner Center of HOPE
CompletedNCT00360594
About this title
Acamprosate Initiated During Alcohol Detoxification
Read the official source — NCT00360594Official study titleInitiating Acamprosate Within Versus Post-detoxification in the Rehabilitative Treatment of Alcohol Dependence.
This study has finished and is no longer accepting participants.
In PhiladelphiaAddictionMedication studyAges 18–70
- Countries
- United States
- Sponsor
- Forest Laboratories